At a glance
ClinicalIndex Comparison Record- ✓Female aged ≥18 years
- ✓High grade serous or high grade endometrioid carcinoma of ovary, fallopian tube, or peritoneum
- ✓Prior platinum treatment (cisplatin or carboplatin)
- ✓Prior PARP inhibitor treatment
- ✕Non-epithelial ovarian cancer, carcinosarcoma, low-grade serous/endometrioid, mucinous, clear-cell carcinomas
- ✕Requiring combination chemotherapy regimens
- ✕Known hypersensitivity to carboplatin
- ✕Persisting ≥grade 2 CTCAE v5 adverse events (except alopecia and neuropathy)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre Phase II Randomised Controlled Trial to Evaluate the Efficacy of Adaptive Therapy (AT) With Carboplatin, Based on Changes in CA125, in Patients With Relapsed Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating Carboplatin for Ovarian Cancer and 6 related conditions. Currently recruiting, targeting 80 participants across 1 site.
Detailed Summary
ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a proxy measure of total tumour burden and an individual patient's response to the most recent chemotherapy treatment. AT could prolong sensitivity to carboplatin and extend tumour control, while simultaneously reducing chemotherapy dose and drug-induced toxicity. Carboplatin is a low cost and low toxicity drug that has an enduring and central role in ovarian cancer treatment.
Study Details
Timeline
Interventions
Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.